Ai Da (Anastrozole) is an essential component of endocrine therapy used to manage cancer that is sensitive to the presence of hormones, primarily in women who have completed menopause. Its therapeutic domain plays a role in managing disease activity across multiple clinical scenarios.

The medication is commonly used across three key therapeutic domains: as a long-term adjuvant treatment to manage the risk of early-stage cancer recurrence, as a first-line therapy for locally advanced or metastatic hormone-positive cancer, and as a second-line strategy for advanced disease that has progressed after prior hormonal treatments. This application is relevant for easing the symptoms related to systemic imbalance and supports patients during difficult episodes by easing distress.

“This medicine is used to help manage the risk of the cancer returning, and may assist with managing symptom clusters that may become intense or disruptive.”

Quick Fact: Relief for Recurrence Risk Management

The therapy is relevant in contexts marked by increased discomfort or tension associated with disease return, and may assist with managing the risk of recurrence in the years following initial diagnosis.

Regulatory References

1. NIH MedlinePlus overview of Anastrozole

Who Can and Cannot Use Ai Da?

Ai Da (Anastrozole) is a prescription medicine with specific eligibility rules strictly defined by regulatory authorities.

Populations That Must Not Use Ai Da (Contraindicated)

Population Group	Regulatory Status
Premenopausal Women	Contraindicated (Not for use in women of premenopausal endocrine status)
Pregnant Women	Contraindicated (Potential for fetal harm)
Breastfeeding Women	Contraindicated (Not recommended)
Hypersensitivity	Contraindicated (Known allergy to Anastrozole or any excipient)

---

Eligibility and Cautionary Use

Use of the medicine is restricted or requires caution in certain populations as noted in the official labeling:

• Pediatric Use: The medicine is not recommended for use in children and adolescents, as efficacy and safety have not been established in this age group.
• Organ Impairment: Caution is advised for patients with severe renal impairment and those with moderate to severe hepatic impairment.
• Comorbidity: Caution is also advised for women with pre-existing ischemic heart disease.
• Older Adults: No dosage adjustment is necessary based on age alone for older adult patients.

Interaction Map: Interactions with other medicines and products — official regulatory information for Ai Da (Anastrozole)

Interaction scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Estrogen-containing therapies (e.g., Hormone Replacement Therapy).
Specific interacting medicines (if explicitly listed)	Tamoxifen (decreased Anastrozole plasma concentration); Warfarin (no alteration to pharmacokinetics or anticoagulant activity).
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic antagonism (with estrogens). Pharmacokinetic alteration (Tamoxifen reduces Anastrozole exposure). Regulatory data supports the unlikelihood of clinically significant inhibition of major cytochrome P450 (CYP) enzymes by Anastrozole.
Timing-based interaction rules (if applicable)	None documented for mandatory spacing of doses.
Population-specific interaction notes (if applicable)	Clearance is approximately 30% lower in patients with stable hepatic cirrhosis.
Interaction-related restrictions	Prohibited co-administration with Estrogen-containing medicinal products and Tamoxifen.

---

Interaction classifications (high-level)

Category	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated/Prohibited (with Estrogens and Tamoxifen). Clinically Insignificant (with food and regarding its effect on CYP substrates).
Regulatory basis (EMA / FDA / etc.)	Consistent with U.S. Food and Drug Administration (FDA) Prescribing Information and European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents)	Co-administration with Tamoxifen or estrogen-containing products results in reduced exposure or counteraction of the drug’s primary effect.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with estrogen-containing medicinal products is prohibited, as this action may diminish the drug's intended pharmacological effect.
• The combination of Anastrozole and Tamoxifen is prohibited, as co-administration is documented to reduce Anastrozole plasma concentration by a clinically relevant degree.
• Official regulatory findings indicate Anastrozole is unlikely to cause clinically significant inhibition of major cytochrome P450 enzymes in the liver, such as CYP3A4.
• It is documented that Anastrozole does not alter the pharmacokinetics or anticoagulant activity of Warfarin.
• Administration with food does not affect the total extent of absorption (AUC).

Connection to the overall interaction profile (3 sentences): The regulatory profile for Ai Da focuses on the necessity of avoiding co-administration with specific hormonal therapies to prevent drug counteraction or reduced exposure. Beyond these prohibited combinations, the drug is officially documented as having a low likelihood of causing significant interactions mediated through the primary CYP enzyme systems. However, a 30% reduction in clearance is noted in patients with stable hepatic cirrhosis, which is a required population-specific pharmacokinetic consideration.

Mechanism 1: Competitive Aromatase Enzyme Inhibition

Ai Da’s core function is to act as a selective, non-steroidal inhibitor of the Aromatase enzyme (CYP19A1). This mechanism involves the molecule reversibly and competitively binding to the enzyme's active site , thereby blocking the enzyme's ability to catalyze the final step of estrogen synthesis. This targeted engagement halts a molecular process in hormone production.

️ Mechanism 2: Systemic Reduction of Estrogen Biosynthesis

By inhibiting the Aromatase enzyme, the drug directly interferes with the Estrogen Biosynthesis Pathway, which converts androgen hormones into estrogens like estradiol (E2). This process primarily occurs in extra-gonadal (peripheral) tissues, such as fat and muscle. The resulting physiological consequence is an extensive and sustained reduction in circulating estrogen levels throughout the body , modifying the hormonal environment influenced by estrogen.

Ai Da is formally provided as an oral tablet and is administered at a uniform dose of one 1 mg tablet taken once daily. This standardized dosing is consistent across officially approved usage contexts, simplifying the systemic endocrine treatment protocol. The administration schedule offers flexibility relative to food, as the tablet may be taken with or without a meal; the tablet is generally taken at approximately the same time each day to maintain consistency.

Crucially, the oral tablet must be swallowed whole, and it is explicitly noted that the tablet should not be crushed, broken, or chewed. If a dose is missed, the standard protocol is to skip that dose if it is almost time for the next scheduled dose, and a double dose is not taken to compensate.

The overall duration of use is dictated by the treatment plan. For individuals receiving therapy in the adjuvant setting, the administration course is typically a fixed period of five years. In cases of advanced disease, the therapy is maintained as part of a long-term plan and continues until there is evidence of disease progression. Dosage adjustment is generally not required for older adults or for patients with renal impairment, and the 1 mg regimen is also stable for those with mild to moderate hepatic impairment.

Research Evidence: Overview of Studies for Ai Da (Anastrozole)

This overview summarizes the official clinical research that has evaluated the medicine Ai Da (Anastrozole). The information describes the types of studies conducted and what the findings, as reported by authoritative sources, suggest about the use of the medicine, without offering any clinical guidance or personal advice.

---

Evidence for Use as Adjuvant Treatment

The foundation of research for Ai Da in the adjuvant setting—meaning after initial primary cancer treatment—is built upon large-scale, international Randomized Controlled Trials (RCTs) evaluated by major regulatory bodies. Research examined endpoints such as Disease-Free Survival (DFS) and Overall Survival (OS) in postmenopausal women with hormone-receptor-positive cancer. Studies reported patterns where the group receiving Ai Da showed differences in measurements of DFS over the initial five-year treatment period when compared to the comparator group. The trials also tracked the incidence measurements of new tumors in the opposite breast, reporting the patterns observed in the studied populations.

Research has explored the effect of extending treatment beyond the core five years. While some studies suggest patterns related to differences in recurrence risk for certain groups, the research is ongoing, and long-term effects are not fully established regarding the optimal total duration of therapy.

Evidence for Use in Advanced Disease (First-Line)

Ai Da was studied for use as a first-line therapy in postmenopausal women with advanced hormone-receptor-positive cancer, according to research evaluated by regulatory bodies. Research examined outcomes such as Time to Progression (TTP), which monitored study-defined episodic changes in disease status, and Objective Response Rate (ORR), which tracked tumor size changes. Studies reported patterns where the group receiving Ai Da showed differences in measurements of TTP when compared to the prior standard agent. Comparative evidence against other, newer hormonal therapies is lacking.

Research Gaps and Areas of Uncertainty

The question of the optimal duration of Ai Da in the adjuvant setting is one such area where data are still emerging. Furthermore, while the evidence is robust for the studied postmenopausal population, data for certain groups remain insufficient, particularly concerning women with complex comorbidities.

Ai Da (Anastrozole) must be stored and handled according to specific regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Storage Requirement	Condition Stipulated by Regulators
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), protecting from heat and freezing.
Protection	Keep protected from light and moisture.
Container	Must be kept in the original, tightly closed container.
Child Safety	Keep out of the sight and reach of children and pets at all times.

Disposal Instructions

Unused or expired Ai Da should be disposed of using a drug take-back program as the preferred method. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance, placed in a sealed bag or container, and discarded in the household trash. The medication must not be flushed down the toilet or discharged into drains or watercourses.